Trametinib is a MEK inhibitor primarily used in the treatment of BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, either alone or in combination with dabrafenib. It is also FDA-approved for the treatment of metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation in combination with dabrafenib, and for locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation in combination with dabrafenib. By inhibiting the MEK enzyme in the MAPK/ERK signaling pathway, trametinib blocks the growth and spread of cancer cells harboring these mutations. This targeted approach minimizes damage to healthy cells compared to traditional chemotherapy. Treatment requires close medical supervision due to potential serious side effects, including heart failure, eye problems (e.g., retinal vein occlusion), rash, and others.